On November 8, 2024, Novo Nordisk A/S disclosed the sale of 6,311,250 shares by board members and executives at a price of DKK 750.42 each, totaling DKK 4,736,088,225.00. This event is categorized under 'Changes in management or control' and is considered significant from an equity investor perspective.